F. L. Aachmann, L. S. Sal, H. Y. Kim, S. M. Marino, V. N. Gladyshev et al., Insights into Function, Catalytic Mechanism, and Fold Evolution of Selenoprotein Methionine Sulfoxide Reductase B1 through Structural Analysis, Journal of Biological Chemistry, vol.1703, issue.43, 2010.
DOI : 10.1074/jbc.M407464200

B. Aressy and B. Ducommun, Cell Cycle Control by the CDC25 Phosphatases, Anti-Cancer Agents in Medicinal Chemistry, vol.8, issue.8, pp.818-824, 2008.
DOI : 10.2174/187152008786847756

E. S. Arner, Focus on mammalian thioredoxin reductases ??? Important selenoproteins with versatile functions, Biochimica et Biophysica Acta (BBA) - General Subjects, vol.1790, issue.6, pp.495-526, 2009.
DOI : 10.1016/j.bbagen.2009.01.014

E. S. Arner, M. Bjornstedt, and A. Holmgren, 1-Chloro-2,4-dinitrobenzene Is an Irreversible Inhibitor of Human Thioredoxin Reductase, Journal of Biological Chemistry, vol.38, issue.8, pp.3479-3482, 1995.
DOI : 10.1016/0006-291X(90)91961-Q

E. S. Arner and A. Holmgren, The thioredoxin system in cancer, Seminars in Cancer Biology, vol.16, issue.6, pp.420-426, 2006.
DOI : 10.1016/j.semcancer.2006.10.009

E. S. Arner, H. Nakamura, T. Sasada, J. Yodoi, A. Holmgren et al., Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cisdiamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex, Free Radic Biol Med, issue.10, pp.31-1170, 2001.

R. Bagheri-yarmand, A. Nanos-webb, A. Biernacka, T. Bui, and K. Keyomarsi, Cyclin E Deregulation Impairs Mitotic Progression through Premature Activation of Cdc25C, Cancer Research, vol.70, issue.12, pp.5085-5095, 2010.
DOI : 10.1158/0008-5472.CAN-09-4095

A. F. Baker, T. Dragovich, W. R. Tate, R. K. Ramanathan, D. Roe et al., The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma, Journal of Laboratory and Clinical Medicine, vol.147, issue.2, pp.83-90, 2006.
DOI : 10.1016/j.lab.2005.09.001

B. Baratte, L. Meijer, K. Galaktionov, and D. Beach, Screening for antimitotic compounds using the cdc25 tyrosine phosphatase, an activator of the mitosis-inducing p34cdc2/cyclin Bcdc13 protein kinase, Anticancer Res, vol.12, issue.3, pp.873-880, 1992.

J. Mann and E. W. Lam, H2O2 induces a transient multi-phase cell cycle arrest in mouse fibroblasts through modulating cyclin D and p21Cip1 expression, J Biol Chem, vol.277, issue.16, pp.13761-13770, 2002.

S. Barranco-medina, J. J. Lazaro, and K. J. Dietz, The oligomeric conformation of peroxiredoxins links redox state to function, FEBS Letters, vol.104, issue.12, pp.1809-1816, 2009.
DOI : 10.1016/S1369-7021(05)71078-6

J. Bartek, R. Iggo, J. Gannon, and D. P. Lane, Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines, Oncogene, vol.5, issue.6, pp.893-899, 1990.

C. Beauchamp and I. Fridovich, Superoxide dismutase: Improved assays and an assay applicable to acrylamide gels, Analytical Biochemistry, vol.44, issue.1, pp.276-287, 1971.
DOI : 10.1016/0003-2697(71)90370-8

J. E. Biaglow and R. A. Miller, The thioredoxin reductase/thioredoxin system: Novel redox targets for cancer therapy, Cancer Biology & Therapy, vol.4, issue.1, pp.6-13, 2005.
DOI : 10.4161/cbt.4.1.1434

H. C. Birnboim and J. Doly, A rapid alkaline extraction procedure for screening recombinant plasmid DNA, Nucleic Acids Research, vol.7, issue.6, pp.1513-1523, 1979.
DOI : 10.1093/nar/7.6.1513

T. Boulikas and M. Vougiouka, Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (Review), Oncology Reports, vol.11, issue.3, pp.559-595, 2004.
DOI : 10.3892/or.11.3.559

R. Boutros, C. Dozier, and B. Ducommun, The when and wheres of CDC25 phosphatases, Current Opinion in Cell Biology, vol.18, issue.2, pp.185-191, 2006.
DOI : 10.1016/j.ceb.2006.02.003

URL : https://hal.archives-ouvertes.fr/hal-00317392

R. Boutros, V. Lobjois, and B. Ducommun, CDC25 phosphatases in cancer cells: key players? Good targets?, Nature Reviews Cancer, vol.20, issue.7, pp.495-507, 2007.
DOI : 10.1158/0008-5472.CAN-05-1054

URL : https://hal.archives-ouvertes.fr/hal-00317350

T. D. Bradshaw, C. S. Matthews, J. Cookson, E. H. Chew, M. Shah et al., Elucidation of Thioredoxin as a Molecular Target for Antitumor Quinols, Cancer Research, vol.65, issue.9, pp.3911-3919, 2005.
DOI : 10.1158/0008-5472.CAN-04-4141

M. Brisson, T. Nguyen, P. Wipf, B. Joo, B. W. Day et al., Redox regulation of Cdc25B by cell active quinolinediones, Molecular Pharmacology, vol.68, issue.6, pp.1810-1820, 2005.
DOI : 10.1124/mol.105.016360

K. K. Brown, A. G. Cox, and M. B. Hampton, Mitochondrial respiratory chain involvement in peroxiredoxin 3 oxidation by phenethyl isothiocyanate and auranofin, FEBS Letters, vol.47, issue.6, pp.1257-1262, 2010.
DOI : 10.1016/j.freeradbiomed.2009.05.027

A. Baumbach, J. G. Sickmann, and . Hengstler, Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer, Breast Cancer Res, vol.12, issue.3, p.44, 2010.

R. Cailleau, R. Young, M. Olive, W. J. Reeves, and J. , Breast Tumor Cell Lines From Pleural Effusions 2, JNCI: Journal of the National Cancer Institute, vol.53, issue.3, pp.661-674, 1974.
DOI : 10.1093/jnci/53.3.661

M. G. Cangi, B. Cukor, P. Soung, S. Signoretti, G. Moreira et al., Role of the Cdc25A phosphatase in human breast cancer, Journal of Clinical Investigation, vol.106, issue.6, pp.753-761, 2000.
DOI : 10.1172/JCI9174

J. Cao, J. Schulte, A. Knight, N. R. Leslie, A. Zagozdzon et al., Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity, Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity, pp.1505-1517, 2009.
DOI : 10.1021/bi00087a012

URL : http://emboj.embopress.org/content/embojnl/28/10/1505.full.pdf

S. Casagrande, V. Bonetto, M. Fratelli, E. Gianazza, I. Eberini et al., Glutathionylation of human thioredoxin: A possible crosstalk between the glutathione and thioredoxin systems, Proceedings of the National Academy of Sciences, vol.17, issue.9, pp.99-9745, 2002.
DOI : 10.1093/emboj/17.9.2596

F. Casali, V. Burgat, and P. Guerre, Le dimethylsulfoxyde (DMSO): principale propriétés et usage autorisés, pp.207-220, 2011.

N. Cenas, S. Prast, H. Nivinskas, J. Sarlauskas, and E. S. Arner, Interactions of Nitroaromatic Compounds with the Mammalian Selenoprotein Thioredoxin Reductase and the Relation to Induction of Apoptosis in Human Cancer Cells, Journal of Biological Chemistry, vol.18, issue.9, pp.5593-5603, 2006.
DOI : 10.1128/AEM.68.4.1690-1696.2002

V. Cepeda, M. A. Fuertes, J. Castilla, C. Alonso, C. Quevedo et al., Biochemical Mechanisms of Cisplatin Cytotoxicity, Anti-Cancer Agents in Medicinal Chemistry, vol.7, issue.1, pp.3-18, 2007.
DOI : 10.2174/187152007779314044

M. K. Cha, K. H. Suh, and I. H. Kim, Overexpression of peroxiredoxin I and thioredoxin1 in human breast carcinoma, Journal of Experimental & Clinical Cancer Research, vol.28, issue.1, p.93, 2009.
DOI : 10.1186/1756-9966-28-93

C. Y. Chen, D. Willard, and J. Rudolph, Redox Regulation of SH2-Domain-Containing Protein Tyrosine Phosphatases by Two Backdoor Cysteines, Biochemistry, vol.48, issue.6, pp.1399-1409, 2009.
DOI : 10.1021/bi801973z

X. P. Chen, S. Liu, W. X. Tang, and Z. W. Chen, Nuclear thioredoxin-1 is required to suppress cisplatin-mediated apoptosis of MCF-7 cells, Biochemical and Biophysical Research Communications, vol.361, issue.2, pp.362-366, 2007.
DOI : 10.1016/j.bbrc.2007.07.033

P. Chiarugi, Survival or Death: The Redox Paradox, Antioxidants & Redox Signaling, vol.11, issue.11, pp.2651-2654, 2009.
DOI : 10.1089/ars.2009.2770

P. Chiarugi and F. Buricchi, Protein Tyrosine Phosphorylation and Reversible Oxidation: Two Cross-Talking Posttranslation Modifications, Antioxidants & Redox Signaling, vol.9, issue.1, pp.1-24, 2007.
DOI : 10.1089/ars.2007.9.1

P. Chiarugi and P. Cirri, Redox regulation of protein tyrosine phosphatases during receptor tyrosine kinase signal transduction, Trends in Biochemical Sciences, vol.28, issue.9, pp.509-514, 2003.
DOI : 10.1016/S0968-0004(03)00174-9

G. Galeotti and . Ramponi, Reactive oxygen species as essential mediators of cell adhesion: the oxidative inhibition of a FAK tyrosine phosphatase is required for cell adhesion, J Cell Biol, vol.161, issue.5, pp.933-944, 2003.

S. H. Cho, C. H. Lee, Y. Ahn, H. Kim, H. Kim et al., -mediated cell signaling, FEBS Letters, vol.425, issue.1-3, pp.1-3, 2004.
DOI : 10.1038/nature02075

P. J. Chua, G. W. Yip, and B. H. Bay, Cell Cycle Arrest Induced by Hydrogen Peroxide Is Associated with Modulation of Oxidative Stress Related Genes in Breast Cancer Cells, Experimental Biology and Medicine, vol.234, issue.9, pp.1086-1094, 2009.
DOI : 10.1074/jbc.M111123200

J. F. Collet and J. Messens, Structure, Function, and Mechanism of Thioredoxin Proteins, Antioxidants & Redox Signaling, vol.13, issue.8, 2010.
DOI : 10.1089/ars.2010.3114

A. G. Cox, K. K. Brown, E. S. Arner, and M. B. Hampton, The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation, Biochemical Pharmacology, vol.76, issue.9, pp.1097-1109, 2008.
DOI : 10.1016/j.bcp.2008.08.021

A. G. Cox, C. C. Winterbourn, and M. B. Hampton, Mitochondrial peroxiredoxin involvement in antioxidant defence and redox signalling, Biochemical Journal, vol.839, issue.2, pp.313-325, 2010.
DOI : 10.1074/jbc.M801047200

R. C. Cumming, N. L. Andon, P. A. Haynes, M. Park, W. H. Fischer et al., Protein Disulfide Bond Formation in the Cytoplasm during Oxidative Stress, Journal of Biological Chemistry, vol.267, issue.21, pp.21749-21758, 2004.
DOI : 10.1074/jbc.M313721200

I. Dalle-donne, R. Rossi, G. Colombo, D. Giustarini, and A. Milzani, Protein S-glutathionylation: a regulatory device from bacteria to humans, Trends in Biochemical Sciences, vol.34, issue.2, pp.85-96, 2009.
DOI : 10.1016/j.tibs.2008.11.002

M. Z. De-pina, H. Vazquez-meza, J. P. Pardo, J. L. Rendon, R. Villalobos-molina et al., and Reactivation by Thioredoxin, Journal of Biological Chemistry, vol.50, issue.18, pp.12373-12386, 2008.
DOI : 10.1002/prot.20825

D. Douer and M. S. Tallman, Arsenic Trioxide: New Clinical Experience With an Old Medication in Hematologic Malignancies, Journal of Clinical Oncology, vol.23, issue.10, pp.2396-2410, 2005.
DOI : 10.1200/JCO.2005.10.217

M. Ennen, V. Minig, S. Grandemange, N. Touche, J. L. Merlin et al., Regulation of the high basal expression of the manganese superoxide dismutase gene in aggressive breast cancer cells, Free Radical Biology and Medicine, vol.50, issue.12, pp.1771-1779, 2011.
DOI : 10.1016/j.freeradbiomed.2011.03.013

URL : https://hal.archives-ouvertes.fr/hal-00747766

S. E. Eriksson, S. Prast-nielsen, E. Flaberg, L. Szekely, and E. S. Arner, High levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy, Free Radical Biology and Medicine, vol.47, issue.11, pp.1661-1671, 2009.
DOI : 10.1016/j.freeradbiomed.2009.09.016

H. Esterbauer, R. J. Schaur, and H. Zollner, Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes, Free Radical Biology and Medicine, vol.11, issue.1, pp.81-128, 1991.
DOI : 10.1016/0891-5849(91)90192-6

A. M. Evens, P. Lecane, D. Magda, S. Prachand, S. Singhal et al., Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells, Blood, vol.105, issue.3, pp.1265-1273, 2005.
DOI : 10.1182/blood-2004-03-0964

J. Fang, J. Lu, and A. Holmgren, Thioredoxin Reductase Is Irreversibly Modified by Curcumin, Journal of Biological Chemistry, vol.11, issue.26, pp.25284-25290, 2005.
DOI : 10.1016/j.drup.2004.01.004

URL : http://www.jbc.org/content/280/26/25284.full.pdf

A. R. Farina, A. Tacconelli, L. Cappabianca, M. P. Masciulli, A. Holmgren et al., Thioredoxin alters the matrix metalloproteinase/tissue inhibitors of metalloproteinase balance and stimulates human SK-N-SH neuroblastoma cell invasion, European Journal of Biochemistry, vol.257, issue.112, pp.405-413, 2001.
DOI : 10.1006/bbrc.1999.0408

H. J. Forman, M. Maiorino, and F. Ursini, Signaling Functions of Reactive Oxygen Species, Biochemistry, vol.49, issue.5, pp.835-842, 2010.
DOI : 10.1021/bi9020378

S. Fourquet, M. E. Huang, B. D. Autreaux, and M. B. Toledano, Scavenging and Signaling, Antioxidants & Redox Signaling, vol.10, issue.9, pp.1565-1576, 2008.
DOI : 10.1089/ars.2008.2049

G. Fujino, T. Noguchi, K. Takeda, and H. Ichijo, Thioredoxin and protein kinases in redox signaling, Seminars in Cancer Biology, vol.16, issue.6, pp.427-435, 2006.
DOI : 10.1016/j.semcancer.2006.09.003

A. Furuhata, M. Nakamura, T. Osawa, and K. Uchida, Thiolation of Protein-bound Carcinogenic Aldehyde, Journal of Biological Chemistry, vol.964, issue.7, pp.27919-27926, 2002.
DOI : 10.1016/0003-2697(76)90326-2

B. G. Gabrielli, J. M. Clark, A. K. Mccormack, and K. A. Ellem, Hyperphosphorylation of the N-terminal Domain of Cdc25 Regulates Activity toward Cyclin B1/Cdc2 But Not Cyclin A/Cdk2, Journal of Biological Chemistry, vol.101, issue.45, pp.28607-28614, 1997.
DOI : 10.1038/sj.onc.1201254

L. Gan, X. L. Yang, Q. Liu, and H. B. Xu, Inhibitory effects of thioredoxin reductase antisense RNA on the growth of human hepatocellular carcinoma cells, Journal of Cellular Biochemistry, vol.97, issue.3, pp.653-664, 2005.
DOI : 10.1101/SQB.1994.059.01.035

A. Bindoli, R. Sturaro, C. Rella, and . Marzano, Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase, Biochem Pharmacol, vol.79, issue.2, pp.90-101, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00535818

P. A. Garner-hamrick and C. Fisher, Antisense phosphorothioate oligonucleotides specifically down-regulate cdc25B causing S-phase delay and persistent antiproliferative effects, International Journal of Cancer, vol.271, issue.5, pp.720-728, 1998.
DOI : 10.1074/jbc.271.9.5118

E. Gelhaye, N. Rouhier, and J. P. Jacquot, that requires GSH/Grx for its reduction, FEBS Letters, vol.278, issue.3, pp.443-448, 2003.
DOI : 10.1074/jbc.M303477200

M. Giorgio, M. Trinei, E. Migliaccio, and P. G. Pelicci, Hydrogen peroxide: a metabolic by-product or a common mediator of ageing signals?, Nature Reviews Molecular Cell Biology, vol.25, issue.9, pp.722-728, 2007.
DOI : 10.1093/gerona/61.1.36

Y. M. Go, P. J. Halvey, J. M. Hansen, M. Reed, J. Pohl et al., Reactive Aldehyde Modification of Thioredoxin-1 Activates Early Steps of Inflammation and Cell Adhesion, The American Journal of Pathology, vol.171, issue.5, pp.1670-1681, 2007.
DOI : 10.2353/ajpath.2007.070218

M. E. Goetz and A. Luch, Reactive species: A cell damaging rout assisting to chemical carcinogens, Cancer Letters, vol.266, issue.1, pp.73-83, 2008.
DOI : 10.1016/j.canlet.2008.02.035

G. Groeger, C. Quiney, and T. G. Cotter, Hydrogen Peroxide as a Cell-Survival Signaling Molecule, Antioxidants & Redox Signaling, vol.11, issue.11, pp.2655-2671, 2009.
DOI : 10.1089/ars.2009.2728

S. Gromer, L. D. Arscott, C. H. Williams, J. , R. H. Schirmer et al., Human Placenta Thioredoxin Reductase, Journal of Biological Chemistry, vol.332, issue.32, pp.20096-20101, 1998.
DOI : 10.1042/bj3320591

S. Gromer, S. Urig, and K. Becker, The thioredoxin system?From science to clinic, Medicinal Research Reviews, vol.278, issue.1, pp.40-89, 2004.
DOI : 10.1074/jbc.M303762200

W. H. Habig, M. J. Pabst, and W. B. Jakoby, Glutathione S-transferases. The first enzymatic step in mercapturic acid formation, J Biol Chem, vol.249, issue.22, pp.7130-7139, 1974.

D. Hanahan and R. A. Weinberg, The Hallmarks of Cancer, Cell, vol.100, issue.1, pp.57-70, 2000.
DOI : 10.1016/S0092-8674(00)81683-9

S. I. Hashemy, J. S. Ungerstedt, F. Z. Avval, and A. Holmgren, Motexafin Gadolinium, a Tumor-selective Drug Targeting Thioredoxin Reductase and Ribonucleotide Reductase, Journal of Biological Chemistry, vol.296, issue.16, pp.10691-10697, 2006.
DOI : 10.1093/emboj/17.9.2596

W. C. Hawkes and Z. Alkan, Regulation of Redox Signaling by Selenoproteins, Biological Trace Element Research, vol.66, issue.Spec No 1, pp.235-251, 2010.
DOI : 10.1016/j.bbagen.2009.03.002

E. Hedstrom, S. Eriksson, J. Zawacka-pankau, E. S. Arner, and G. Selivanova, p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA, Cell Cycle, vol.8, issue.21, pp.3576-3583, 2009.
DOI : 10.4161/cc.8.21.9977

E. O. Hileman, J. Liu, M. Albitar, M. J. Keating, and P. Huang, Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity, Cancer Chemotherapy and Pharmacology, vol.53, issue.3, pp.209-219, 2004.
DOI : 10.1007/s00280-003-0726-5

A. Holmgren, Bovine thioredoxin system. Purification of thioredoxin reductase from calf liver and thymus and studies of its function in disulfide reduction, J Biol Chem, vol.252, issue.13, pp.4600-4606, 1977.

A. Holmgren and J. Lu, Thioredoxin and thioredoxin reductase: Current research with special reference to human disease, Biochemical and Biophysical Research Communications, vol.396, issue.1, pp.120-124, 2010.
DOI : 10.1016/j.bbrc.2010.03.083

Y. Honaker and H. Piwnica-worms, Casein kinase 1 functions as both penultimate and ultimate kinase in regulating Cdc25A destruction, Oncogene, vol.6, issue.23, pp.3324-3334, 2010.
DOI : 10.1128/MCB.19.9.6379

N. D. Horton, B. M. Mamiya, and J. P. Kehrer, Relationships between cell density, glutathione and proliferation of A549 human lung adenocarcinoma cells treated with acrolein, Toxicology, vol.122, issue.1-2, pp.111-122, 1997.
DOI : 10.1016/S0300-483X(97)00086-3

M. Isoda, Y. Kanemori, N. Nakajo, S. Uchida, K. Yamashita et al., The Extracellular Signal-regulated Kinase-Mitogen-activated Protein Kinase Pathway Phosphorylates and Targets Cdc25A for SCF??-TrCP-dependent Degradation for Cell Cycle Arrest, Molecular Biology of the Cell, vol.20, issue.8, pp.2186-2195, 2009.
DOI : 10.1091/mbc.E09-01-0008

Y. Ito, H. Yoshida, T. Uruno, Y. Takamura, A. Miya et al., Expression of cdc25A and cdc25B phosphatase in breast carcinoma, Breast Cancer, vol.9, issue.3, pp.295-300, 2004.
DOI : 10.1038/bjc.1997.261

E. A. Jaimes, E. G. Demaster, R. X. Tian, and L. Raij, Stable Compounds of Cigarette Smoke Induce Endothelial Superoxide Anion Production via NADPH Oxidase Activation, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.24, issue.6, pp.1031-1036, 2004.
DOI : 10.1161/01.ATV.0000127083.88549.58

D. T. Jones, C. W. Pugh, S. Wigfield, M. F. Stevens, and A. L. Harris, Novel Thioredoxin Inhibitors Paradoxically Increase Hypoxia-Inducible Factor-?? Expression but Decrease Functional Transcriptional Activity, DNA Binding, and Degradation, Clinical Cancer Research, vol.12, issue.18, pp.5384-5394, 2006.
DOI : 10.1158/1078-0432.CCR-05-2380

D. Jullien, B. Bugler, C. Dozier, M. Cazales, and B. Ducommun, Identification of N-Terminally Truncated Stable Nuclear Isoforms of CDC25B That Are Specifically Involved in G2/M Checkpoint Recovery, Cancer Research, vol.71, issue.5, pp.1968-1977, 2011.
DOI : 10.1158/0008-5472.CAN-10-2453

K. Kahlos, J. Zhang, E. R. Block, and J. M. Patel, Thioredoxin restores nitric oxide-induced inhibition of protein kinase C activity in lung endothelial cells, Molecular and Cellular Biochemistry, vol.254, issue.1/2, pp.47-54, 2003.
DOI : 10.1023/A:1027380828645

A. M. Kaimul, H. Nakamura, H. Masutani, and J. Yodoi, Thioredoxin and thioredoxin-binding protein-2 in cancer and metabolic syndrome, Free Radical Biology and Medicine, vol.43, issue.6, pp.861-868, 2007.
DOI : 10.1016/j.freeradbiomed.2007.05.032

S. W. Kang, S. G. Rhee, T. S. Chang, W. Jeong, and M. H. Choi, 2-Cys peroxiredoxin function in intracellular signal transduction: therapeutic implications, Trends in Molecular Medicine, vol.11, issue.12, pp.571-578, 2005.
DOI : 10.1016/j.molmed.2005.10.006

T. Kang, Y. Wei, Y. Honaker, H. Yamaguchi, E. Appella et al., GSK-3?? Targets Cdc25A for Ubiquitin-Mediated Proteolysis, and GSK-3?? Inactivation Correlates with Cdc25A Overproduction in Human Cancers, Cancer Cell, vol.13, issue.1, pp.36-47, 2008.
DOI : 10.1016/j.ccr.2007.12.002

C. Karlsson-rosenthal and J. B. Millar, Cdc25: mechanisms of checkpoint inhibition and recovery, Trends in Cell Biology, vol.16, issue.6, pp.285-292, 2006.
DOI : 10.1016/j.tcb.2006.04.002

Z. Kattan, V. Minig, P. Leroy, M. Dauca, and P. Becuwe, Role of manganese superoxide dismutase on growth and invasive properties of human estrogen-independent breast cancer cells, Breast Cancer Research and Treatment, vol.8, issue.2, pp.203-215, 2008.
DOI : 10.1128/MCB.17.7.3629

W. F. Kean and I. R. Kean, Clinical pharmacology of gold, Inflammopharmacology, vol.16, issue.3, pp.112-125, 2008.
DOI : 10.1007/s10787-007-0021-x

J. P. Kehrer and S. S. Biswal, The Molecular Effects of Acrolein, Toxicological Sciences, vol.57, issue.1, pp.6-15, 2000.
DOI : 10.1093/toxsci/57.1.6

A. Kim, S. Joseph, A. Khan, C. J. Epstein, R. Sobel et al., Enhanced expression of mitochondrial superoxide dismutase leads to prolonged in vivo cell cycle progression and up-regulation of mitochondrial thioredoxin, Free Radical Biology and Medicine, vol.48, issue.11, pp.1501-1512, 2010.
DOI : 10.1016/j.freeradbiomed.2010.02.028

A. Kim, W. Zhong, and T. D. Oberley, Reversible Modulation of Cell Cycle Kinetics in NIH/3T3 Mouse Fibroblasts by Inducible Overexpression of Mitochondrial Manganese Superoxide Dismutase, Antioxidants & Redox Signaling, vol.6, issue.3, pp.489-500, 2004.
DOI : 10.1089/152308604773934251

S. J. Kim, Y. Miyoshi, T. Taguchi, Y. Tamaki, H. Nakamura et al., High Thioredoxin Expression Is Associated with Resistance to Docetaxel in Primary Breast Cancer, Clinical Cancer Research, vol.11, issue.23, pp.8425-8430, 2005.
DOI : 10.1158/1078-0432.CCR-05-0449

S. K. Kim, J. W. Yang, M. R. Kim, S. H. Roh, H. G. Kim et al., Increased expression of Nrf2/ARE-dependent anti-oxidant proteins in tamoxifen-resistant breast cancer cells, Free Radical Biology and Medicine, vol.45, issue.4, pp.537-546, 2008.
DOI : 10.1016/j.freeradbiomed.2008.05.011

G. Angulo and . Powis, Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides, Biochem Pharmacol, vol.55, issue.7, pp.987-994, 1998.

D. L. Kirkpatrick, S. Watson, M. Kunkel, S. Fletcher, S. Ulhaq et al., Parallel syntheses of disulfide inhibitors of the thioredoxin redox system as potential antitumor agents, Anticancer Drug Des, vol.14, issue.5, pp.421-432, 1999.

H. Kiyokawa and D. Ray, In Vivo Roles of CDC25 Phosphatases: Biological Insight into the Anti-Cancer Therapeutic Targets, Anti-Cancer Agents in Medicinal Chemistry, vol.8, issue.8, pp.832-836, 2008.
DOI : 10.2174/187152008786847693

K. Kristjansdottir and J. Rudolph, Cdc25 Phosphatases and Cancer, Chemistry & Biology, vol.11, issue.8, pp.1043-1051, 2004.
DOI : 10.1016/j.chembiol.2004.07.007

B. Kumar, S. Koul, L. Khandrika, R. B. Meacham, and H. K. , Oxidative Stress Is Inherent in Prostate Cancer Cells and Is Required for Aggressive Phenotype, Cancer Research, vol.68, issue.6, pp.1777-1785, 2008.
DOI : 10.1158/0008-5472.CAN-07-5259

M. W. Kunkel, D. L. Kirkpatrick, J. I. Johnson, and G. Powis, Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs, Anticancer Drug Des, vol.12, issue.8, pp.659-670, 1997.

F. Lacombe and F. Belloc, Flow cytometry study of cell cycle, apoptosis and drug resistance in acute leukemia, Hematology and Cell Therapy, vol.38, issue.6, pp.495-504, 1996.
DOI : 10.1007/s00282-996-0495-9

U. K. Laemmli, Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4, Nature, vol.244, issue.5259, pp.680-685, 1970.
DOI : 10.1101/SQB.1963.028.01.053

A. J. Lambert and M. D. Brand, Reactive Oxygen Species Production by Mitochondria, Methods Mol Biol, vol.554, pp.165-181, 2009.
DOI : 10.1007/978-1-59745-521-3_11

J. Laoukili, M. Stahl, and R. H. Medema, FoxM1: At the crossroads of ageing and cancer, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol.1775, issue.1, pp.92-102, 2007.
DOI : 10.1016/j.bbcan.2006.08.006

A. Lavecchia, C. D. Giovanni, and E. Novellino, CDC25A and B Dual-Specificity Phosphatase Inhibitors: Potential Agents for Cancer Therapy, Current Medicinal Chemistry, vol.16, issue.15, pp.1831-1849, 2009.
DOI : 10.2174/092986709788186084

C. P. Lebel, H. Ischiropoulos, and S. C. Bondy, Evaluation of the probe 2',7'-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress, Chemical Research in Toxicology, vol.5, issue.2, pp.227-231, 1992.
DOI : 10.1021/tx00026a012

B. C. Lee, A. Dikiy, H. Y. Kim, and V. N. Gladyshev, Functions and evolution of selenoprotein methionine sulfoxide reductases, Biochimica et Biophysica Acta (BBA) - General Subjects, vol.1790, issue.11, pp.1790-1471, 2009.
DOI : 10.1016/j.bbagen.2009.04.014

S. R. Lee, K. S. Kwon, S. R. Kim, and S. G. Rhee, Reversible Inactivation of Protein-tyrosine Phosphatase 1B in A431 Cells Stimulated with Epidermal Growth Factor, Journal of Biological Chemistry, vol.11, issue.25, pp.15366-15372, 1998.
DOI : 10.1126/science.279.5347.88

Y. J. Lee, J. H. Kim, J. Chen, and J. J. Song, Enhancement of Metabolic Oxidative Stress-Induced Cytotoxicity by the Thioredoxin Inhibitor 1-Methylpropyl 2-Imidazolyl Disulfide Is Mediated through the ASK1-SEK1-JNK1 Pathway, Molecular Pharmacology, vol.62, issue.6, pp.1409-1417, 2002.
DOI : 10.1124/mol.62.6.1409

K. J. Lenton, H. Therriault, and J. R. Wagner, Analysis of Glutathione and Glutathione Disulfide in Whole Cells and Mitochondria by Postcolumn Derivatization High-Performance Liquid Chromatography with ortho-Phthalaldehyde, Analytical Biochemistry, vol.274, issue.1, pp.125-130, 1999.
DOI : 10.1006/abio.1999.4258

N. R. Leslie, D. Bennett, Y. E. Lindsay, H. Stewart, A. Gray et al., Redox regulation of PI 3-kinase signalling via inactivation of PTEN, The EMBO Journal, vol.22, issue.20, pp.5501-5510, 2003.
DOI : 10.1093/emboj/cdg513

L. Li, L. Jiang, C. Geng, J. Cao, and L. Zhong, The role of oxidative stress in acrolein-induced DNA damage in HepG2 cells, Free Radical Research, vol.103, issue.4, pp.354-361, 2008.
DOI : 10.1073/pnas.0607031103

N. Li and T. D. Oberley, Modulation of antioxidant enzymes, reactive oxygen species, and glutathione levels in manganese superoxide dismutase-overexpressing NIH/3T3 fibroblasts during the cell cycle, Journal of Cellular Physiology, vol.14, issue.1, pp.148-160, 1998.
DOI : 10.1038/sj.onc.1200852

D. T. Lincoln, E. M. Ali-emadi, K. F. Tonissen, and F. M. Clarke, The thioredoxinthioredoxin reductase system: over-expression in human cancer, Anticancer Res, vol.23, issue.3B, pp.2425-2433, 2003.

A. Lindqvist, H. Kallstrom, A. Lundgren, E. Barsoum, and C. K. Rosenthal, Cdc25B cooperates with Cdc25A to induce mitosis but has a unique role in activating cyclin B1???Cdk1 at the centrosome, The Journal of Cell Biology, vol.269, issue.1, pp.35-45, 2005.
DOI : 10.1074/jbc.M305178200

B. Liu, Y. Chen, and D. K. St-clair, ROS and p53: A versatile partnership, Free Radical Biology and Medicine, vol.44, issue.8, pp.1529-1535, 2008.
DOI : 10.1016/j.freeradbiomed.2008.01.011

H. Loffler, R. G. Syljuasen, J. Bartkova, J. Worm, J. Lukas et al., Distinct modes of deregulation of the proto-oncogenic Cdc25A phosphatase in human breast cancer cell lines, Oncogene, vol.22, issue.50, pp.8063-8071, 2003.
DOI : 10.1038/35044005

O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall, Protein measurement with the Folin phenol reagent, J Biol Chem, vol.193, issue.1, pp.265-275, 1951.

J. Lu, E. H. Chew, and A. Holmgren, Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide, Proceedings of the National Academy of Sciences, vol.252, issue.5, pp.12288-12293, 2007.
DOI : 10.1006/meth.1995.1025

J. Lu, L. V. Papp, J. Fang, S. Rodriguez-nieto, B. Zhivotovsky et al., Inhibition of Mammalian Thioredoxin Reductase by Some Flavonoids: Implications for Myricetin and Quercetin Anticancer Activity, Cancer Research, vol.66, issue.8, pp.4410-4418, 2006.
DOI : 10.1158/0008-5472.CAN-05-3310

S. M. Ludeman, The chemistry of the metabolites of cyclophosphamide, Curr Pharm Des, vol.5, issue.8, pp.627-643, 1999.

D. Magda and R. A. Miller, Motexafin gadolinium: A novel redox active drug for cancer therapy, Seminars in Cancer Biology, vol.16, issue.6, pp.466-476, 2006.
DOI : 10.1016/j.semcancer.2006.09.002

F. Magherini, A. Modesti, L. Bini, M. Puglia, I. Landini et al., Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study, JBIC Journal of Biological Inorganic Chemistry, vol.49, issue.4, pp.573-582, 2010.
DOI : 10.1038/emm.2002.38

L. J. Mah, A. El-osta, and T. C. Karagiannis, ??H2AX: a sensitive molecular marker of DNA damage and repair, Leukemia, vol.678, issue.4, pp.679-686, 2010.
DOI : 10.1002/cyto.a.20426

N. Mailand, A. V. Podtelejnikov, A. Groth, M. Mann, J. Bartek et al., Regulation of G2/M events by Cdc25A through phosphorylation-dependent modulation of its stability, The EMBO Journal, vol.21, issue.21, pp.5911-5920, 2002.
DOI : 10.1093/emboj/cdf567

M. Malumbres and M. Barbacid, Cell cycle, CDKs and cancer: a changing paradigm, Nature Reviews Cancer, vol.436, issue.3, pp.153-166, 2009.
DOI : 10.1101/gad.8.1.9

P. A. Marks, Thioredoxin in cancer???Role of histone deacetylase inhibitors, Seminars in Cancer Biology, vol.16, issue.6, pp.436-443, 2006.
DOI : 10.1016/j.semcancer.2006.09.005

C. Marzano, V. Gandin, A. Folda, G. Scutari, A. Bindoli et al., Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells, Free Radical Biology and Medicine, vol.42, issue.6, pp.872-881, 2007.
DOI : 10.1016/j.freeradbiomed.2006.12.021

H. Masutani, S. Ueda, and J. Yodoi, The thioredoxin system in retroviral infection and apoptosis, Cell Death & Differentiation, vol.3, issue.S1, pp.991-998, 2005.
DOI : 10.1128/JVI.77.5.3319-3325.2003

H. Masutani, S. Ueda, and J. Yodoi, The thioredoxin system in retroviral infection and apoptosis, Cell Death & Differentiation, vol.3, issue.S1, pp.991-998, 2005.
DOI : 10.1128/JVI.77.5.3319-3325.2003

J. R. Matthews, N. Wakasugi, J. L. Virelizier, J. Yodoi, and R. T. Hay, Thiordoxin regulates the DNA binding activity of NF-??B by reduction of a disulphid bond involving cysteine 62, Nucleic Acids Research, vol.20, issue.15, pp.3821-3830, 1992.
DOI : 10.1093/nar/20.15.3821

T. C. Meng, D. A. Buckley, S. Galic, T. Tiganis, and N. K. Tonks, Regulation of Insulin Signaling through Reversible Oxidation of the Protein-tyrosine Phosphatases TC45 and PTP1B, Journal of Biological Chemistry, vol.114, issue.36, pp.37716-37725, 2004.
DOI : 10.1038/sj.onc.1201279

T. C. Meng, T. Fukada, and N. K. Tonks, Reversible Oxidation and Inactivation of Protein Tyrosine Phosphatases In Vivo, Molecular Cell, vol.9, issue.2, pp.387-399, 2002.
DOI : 10.1016/S1097-2765(02)00445-8

V. Milacic, D. Fregona, and Q. P. Dou, Gold complexes as prospective metal-based anticancer drugs, Histol Histopathol, vol.23, issue.1, pp.101-108, 2008.

W. H. Miller and . Jr, Molecular Targets of Arsenic Trioxide in Malignant Cells, The Oncologist, vol.7, issue.90001, 2002.
DOI : 10.1634/theoncologist.7-suppl_1-14

W. H. Miller, H. M. Jr, J. S. Schipper, J. Lee, S. Singer et al., Mechanisms of action of arsenic trioxide, Cancer Res, vol.62, issue.14, pp.3893-3903, 2002.

D. A. Mitchell, S. U. Morton, N. B. Fernhoff, and M. A. Marletta, Thioredoxin is required for S-nitrosation of procaspase-3 and the inhibition of apoptosis in Jurkat cells, Proceedings of the National Academy of Sciences, vol.169, issue.9, pp.11609-11614, 2007.
DOI : 10.4049/jimmunol.169.9.4805

P. A. Mitozo, L. F. De-souza, G. Loch-neckel, S. Flesch, A. F. Maris et al., A study of the relative importance of the peroxiredoxin-, catalase-, and glutathione-dependent systems in neural peroxide metabolism, Free Radical Biology and Medicine, vol.51, issue.1, pp.69-77, 2011.
DOI : 10.1016/j.freeradbiomed.2011.03.017

A. Mukherjee and S. G. Martin, The thioredoxin system: a key target in tumour and endothelial cells, The British Journal of Radiology, vol.81, issue.special_issue_1, pp.57-68, 2008.
DOI : 10.1016/j.febslet.2006.03.029

A. Mukherjee, A. D. Westwell, T. D. Bradshaw, M. F. Stevens, J. Carmichael et al., Cytotoxic and antiangiogenic activity of AW464 (NSC 706704), a novel thioredoxin inhibitor: an in vitro study, British Journal of Cancer, vol.279, issue.112, pp.350-358, 2005.
DOI : 10.1074/jbc.M310164200

D. Mustacich and G. Powis, Thioredoxin reductase, Biochemical Journal, vol.346, issue.1, pp.1-8, 2000.
DOI : 10.1042/bj3460001

C. R. Myers and J. M. Myers, The effects of acrolein on peroxiredoxins, thioredoxins, and thioredoxin reductase in human bronchial epithelial cells, Toxicology, vol.257, issue.1-2, pp.95-104, 2009.
DOI : 10.1016/j.tox.2008.12.013

J. M. Myers, W. E. Antholine, and C. R. Myers, Hexavalent chromium causes the oxidation of thioredoxin in human bronchial epithelial cells, Toxicology, vol.246, issue.2-3, pp.222-233, 2008.
DOI : 10.1016/j.tox.2008.01.017

J. M. Myers and C. R. Myers, The effects of hexavalent chromium on thioredoxin reductase and peroxiredoxins in human bronchial epithelial cells, Free Radical Biology and Medicine, vol.47, issue.10, pp.1477-1485, 2009.
DOI : 10.1016/j.freeradbiomed.2009.08.015

P. J. Nadeau, S. J. Charette, M. B. Toledano, and J. Landry, Disulfide Bond-mediated Multimerization of Ask1 and Its Reduction by Thioredoxin-1 Regulate H2O2-induced c-Jun NH2-terminal Kinase Activation and Apoptosis, Molecular Biology of the Cell, vol.18, issue.10, pp.3903-3913, 2007.
DOI : 10.1091/mbc.E07-05-0491

H. Nakamura, Y. Hoshino, H. Okuyama, Y. Matsuo, and J. Yodoi, Thioredoxin 1 delivery as new therapeutics, Advanced Drug Delivery Reviews, vol.61, issue.4, pp.303-309, 2009.
DOI : 10.1016/j.addr.2009.01.003

I. Nakashima, K. Takeda, Y. Kawamoto, Y. Okuno, M. Kato et al., Redox control of catalytic activities of membrane-associated protein tyrosine kinases, Archives of Biochemistry and Biophysics, vol.434, issue.1, pp.3-10, 2005.
DOI : 10.1016/j.abb.2004.06.016

M. Eriksson, E. S. Bjornstedt, G. Arner, and . Spyrou, Overexpression of enzymatically active human cytosolic and mitochondrial thioredoxin reductase in HEK-293 cells. Effect on cell growth and differentiation, J Biol Chem, vol.279, issue.52, pp.54510-54517, 2004.

S. Natsuyama, Y. Noda, M. Yamashita, Y. Nagahama, and T. Mori, Superoxide dismutase and thioredoxin restore defective p34cdc2 kinase activation in mouse two-cell block, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol.1176, issue.1-2, pp.90-94, 1993.
DOI : 10.1016/0167-4889(93)90182-O

C. A. Neumann, J. Cao, and Y. Manevich, Peroxiredoxin 1 and its role in cell signaling, Cell Cycle, vol.8, issue.24, pp.4072-4078, 2009.
DOI : 10.4161/cc.8.24.10242

S. Nobili, E. Mini, I. Landini, C. Gabbiani, A. Casini et al., Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies, Medicinal Research Reviews, vol.4, issue.3, pp.550-580, 2010.
DOI : 10.1039/a702757e

J. Nordberg and E. S. Arner, Reactive oxygen species, antioxidants, and the mammalian thioredoxin system1 1This review is based on the licentiate thesis ???Thioredoxin reductase???interactions with the redox active compounds 1-chloro-2,4-dinitrobenzene and lipoic acid??? by Jonas Nordberg, 2001, Karolinska Institute, Stockholm, ISBN 91-631-1064-4., Free Radical Biology and Medicine, vol.31, issue.11, pp.1287-1312, 2001.
DOI : 10.1016/S0891-5849(01)00724-9

J. Nordberg, L. Zhong, A. Holmgren, and E. S. Arner, Mammalian Thioredoxin Reductase Is Irreversibly Inhibited by Dinitrohalobenzenes by Alkylation of Both the Redox Active Selenocysteine and Its Neighboring Cysteine Residue, Journal of Biological Chemistry, vol.28, issue.18, pp.10835-10842, 1998.
DOI : 10.3109/10715769209079515

F. D. Oakley, D. Abbott, Q. Li, and J. F. Engelhardt, Signaling Components of Redox Active Endosomes: The Redoxosomes, Antioxidants & Redox Signaling, vol.11, issue.6, pp.1313-1333, 2009.
DOI : 10.1089/ars.2008.2363

L. W. Oberley, Mechanism of the tumor suppressive effect of MnSOD overexpression, Biomedicine & Pharmacotherapy, vol.59, issue.4, pp.143-148, 2005.
DOI : 10.1016/j.biopha.2005.03.006

I. A. Olovnikov, J. E. Kravchenko, and P. M. Chumakov, Homeostatic functions of the p53 tumor suppressor: Regulation of energy metabolism and antioxidant defense, Seminars in Cancer Biology, vol.19, issue.1, pp.32-41, 2009.
DOI : 10.1016/j.semcancer.2008.11.005

Y. Omata, M. Folan, M. Shaw, R. L. Messer, P. E. Lockwood et al., Sublethal concentrations of diverse gold compounds inhibit mammalian cytosolic thioredoxin reductase (TrxR1), Toxicology in Vitro, vol.20, issue.6, pp.882-890, 2006.
DOI : 10.1016/j.tiv.2006.01.012

E. C. Opara, Oxidative Stress, Disease-a-Month, vol.52, issue.5, pp.183-198, 2006.
DOI : 10.1016/j.disamonth.2006.05.003

M. Ough, A. Lewis, Y. Zhang, M. M. Hinkhouse, J. M. Ritchie et al., Inhibition of Cell Growth by Overexpression of Manganese Superoxide Dismutase (MnSOD) in Human Pancreatic Carcinoma, Free Radical Research, vol.2, issue.6, pp.1223-1233, 2004.
DOI : 10.1074/jbc.M307677200

H. Park, Y. J. Bahn, S. K. Jung, D. G. Jeong, S. H. Lee et al., Discovery of Novel Cdc25 Phosphatase Inhibitors with Micromolar Activity Based on the Structure-Based Virtual Screening, Journal of Medicinal Chemistry, vol.51, issue.18, pp.5533-5541, 2008.
DOI : 10.1021/jm701157g

. Taniguchi, Induction of thioredoxin reductase as an adaptive response to acrolein in human umbilical vein endothelial cells, Biochem Biophys Res Commun, vol.327, issue.4, pp.1058-1065, 2005.

H. Pelicano, D. Carney, and P. Huang, ROS stress in cancer cells and therapeutic implications, Drug Resistance Updates, vol.7, issue.2, pp.97-110, 2004.
DOI : 10.1016/j.drup.2004.01.004

Y. Pereg, B. Y. Liu, K. M. O-'rourke, M. Sagolla, A. Dey et al., Ubiquitin hydrolase Dub3 promotes oncogenic transformation by stabilizing Cdc25A, Nature Cell Biology, vol.7, issue.4, pp.400-406, 2010.
DOI : 10.1038/ncb2041

G. Powis and D. L. Kirkpatrick, Thioredoxin signaling as a target for cancer therapy, Current Opinion in Pharmacology, vol.7, issue.4, pp.392-397, 2007.
DOI : 10.1016/j.coph.2007.04.003

S. Prast-nielsen, M. Cebula, I. Pader, and E. S. Arner, Noble metal targeting of thioredoxin reductase ??? covalent complexes with thioredoxin and thioredoxin-related protein of 14kDa triggered by cisplatin, Free Radical Biology and Medicine, vol.49, issue.11, pp.1765-1778, 2010.
DOI : 10.1016/j.freeradbiomed.2010.09.008

S. J. Vizuete, Q. Berners-price, E. S. Cheng, A. Arner, and . Filipovska, Substrate and inhibitor specificities differ between human cytosolic and mitochondrial thioredoxin reductases: Implications for development of specific inhibitors, Free Radic Biol Med, vol.50, issue.6, pp.689-699, 2011.

J. Raffel, A. K. Bhattacharyya, A. Gallegos, H. Cui, J. G. Einspahr et al., Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival, Journal of Laboratory and Clinical Medicine, vol.142, issue.1, pp.46-51, 2003.
DOI : 10.1016/S0022-2143(03)00068-4

S. J. Ralph, S. Rodriguez-enriquez, J. Neuzil, E. Saavedra, and R. Moreno-sanchez, The causes of cancer revisited: ???Mitochondrial malignancy??? and ROS-induced oncogenic transformation ??? Why mitochondria are targets for cancer therapy, Molecular Aspects of Medicine, vol.31, issue.2, pp.145-170, 2010.
DOI : 10.1016/j.mam.2010.02.008

S. Pestano, D. D. Green, . Von, and . Hoff, A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination, Cancer Chemother Pharmacol, 2010.

R. K. Ramanathan, D. L. Kirkpatrick, C. P. Belani, D. Friedland, S. B. Green et al., A Phase I Pharmacokinetic and Pharmacodynamic Study of PX-12, a Novel Inhibitor of Thioredoxin-1, in Patients with Advanced Solid Tumors, Clinical Cancer Research, vol.13, issue.7, pp.2109-2114, 2007.
DOI : 10.1158/1078-0432.CCR-06-2250

D. Ray and H. Kiyokawa, CDC25A Phosphatase: a Rate-Limiting Oncogene That Determines Genomic Stability, Cancer Research, vol.68, issue.5, pp.1251-1253, 2008.
DOI : 10.1158/0008-5472.CAN-07-5983

E. T. Tsai, H. Papoutsakis, and . Kiyokawa, Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability, Cancer Res, vol.67, issue.3, pp.984-991, 2007.

G. Ray, S. Batra, N. K. Shukla, S. Deo, V. Raina et al., Lipid peroxidation, free radical production and antioxidant status in breast cancer, Breast Cancer Research and Treatment, vol.51, issue.3, pp.163-170, 2000.
DOI : 10.1016/0047-6374(90)90078-T

J. P. Reichheld, M. Khafif, C. Riondet, M. Droux, G. Bonnard et al., Development, The Plant Cell, vol.19, issue.6, pp.1851-1865, 2007.
DOI : 10.1105/tpc.107.050849

URL : https://hal.archives-ouvertes.fr/hal-01579585

H. C. Reinhardt and M. B. Yaffe, Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2, Current Opinion in Cell Biology, vol.21, issue.2, pp.245-255, 2009.
DOI : 10.1016/j.ceb.2009.01.018

S. G. Rhee, CELL SIGNALING: H2O2, a Necessary Evil for Cell Signaling, Science, vol.312, issue.5782, pp.1882-1883, 2006.
DOI : 10.1126/science.1130481

S. G. Rhee, H. Z. Chae, and K. Kim, Peroxiredoxins: A historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling, Free Radical Biology and Medicine, vol.38, issue.12, pp.1543-1552, 2005.
DOI : 10.1016/j.freeradbiomed.2005.02.026

S. G. Rhee, W. Jeong, T. S. Chang, and H. A. Woo, Sulfiredoxin, the cysteine sulfinic acid reductase specific to 2-Cys peroxiredoxin: its discovery, mechanism of action, and biological significance, Kidney International, vol.72, issue.106, pp.3-8, 2007.
DOI : 10.1038/sj.ki.5002380

S. G. Rhee, S. W. Kang, W. Jeong, T. S. Chang, K. S. Yang et al., Intracellular messenger function of hydrogen peroxide and its regulation by peroxiredoxins, Current Opinion in Cell Biology, vol.17, issue.2, pp.183-189, 2005.
DOI : 10.1016/j.ceb.2005.02.004

S. G. Rhee, K. S. Yang, S. W. Kang, H. A. Woo, and T. S. Chang, Controlled elimination of intracellular H(2)O(2): regulation of peroxiredoxin, catalase, and glutathione peroxidase via posttranslational modification, Antioxid Redox Signal, vol.7, pp.5-6, 2005.

L. A. Ridnour, T. D. Oberley, and L. W. Oberley, Tumor Suppressive Effects of MnSOD Overexpression May Involve Imbalance in Peroxide Generation Versus Peroxide Removal, Antioxidants & Redox Signaling, vol.6, issue.3, pp.501-512, 2004.
DOI : 10.1089/152308604773934260

M. P. Rigobello, A. Folda, M. C. Baldoin, G. Scutari, and A. Bindoli, Effect of Auranofin on the mitochondrial generation of hydrogen peroxide. Role of thioredoxin reductase, Free Radical Research, vol.22, issue.7, pp.687-695, 2005.
DOI : 10.1074/jbc.M202026200

M. P. Rigobello, A. Folda, B. Dani, R. Menabo, G. Scutari et al., Gold(I) complexes determine apoptosis with limited oxidative stress in Jurkat T cells, European Journal of Pharmacology, vol.582, issue.1-3, pp.1-3, 2008.
DOI : 10.1016/j.ejphar.2007.12.026

M. P. Rigobello, V. Gandin, A. Folda, A. K. Rundlof, A. P. Fernandes et al., Treatment of human cancer cells with selenite or tellurite in combination with auranofin enhances cell death due to redox shift, Free Radical Biology and Medicine, vol.47, issue.6, pp.710-721, 2009.
DOI : 10.1016/j.freeradbiomed.2009.05.027

M. P. Rigobello, G. Scutari, R. Boscolo, and A. Bindoli, Induction of mitochondrial permeability transition by auranofin, a Gold(I)-phosphine derivative, British Journal of Pharmacology, vol.1241, issue.Suppl., pp.1162-1168, 2002.
DOI : 10.1016/0304-4157(95)00003-A

M. P. Rigobello, G. Scutari, A. Folda, and A. Bindoli, Mitochondrial thioredoxin reductase inhibition by gold(I) compounds and concurrent stimulation of permeability transition and release of cytochrome c, Biochemical Pharmacology, vol.67, issue.4, pp.689-696, 2004.
DOI : 10.1016/j.bcp.2003.09.038

L. Ronconi, C. Marzano, P. Zanello, M. Corsini, G. Miolo et al., Gold(III) Dithiocarbamate Derivatives for the Treatment of Cancer:?? Solution Chemistry, DNA Binding, and Hemolytic Properties, Journal of Medicinal Chemistry, vol.49, issue.5, pp.1648-1657, 2006.
DOI : 10.1021/jm0509288

D. D. Ross, C. C. Joneckis, J. V. Ordonez, A. M. Sisk, R. K. Wu et al., Estimation of cell survival by flow cytometric quantification of fluorescein diacetate/propidium iodide viable cell number, Cancer Res, vol.49, issue.14, pp.3776-3782, 1989.

J. Rudolph, Redox Regulation of the Cdc25 Phosphatases, Antioxidants & Redox Signaling, vol.7, issue.5-6, pp.761-767, 2005.
DOI : 10.1089/ars.2005.7.761

S. W. Ryter, H. P. Kim, A. Hoetzel, J. W. Park, K. Nakahira et al., Mechanisms of Cell Death in Oxidative Stress, Antioxidants & Redox Signaling, vol.9, issue.1, pp.49-89, 2007.
DOI : 10.1089/ars.2007.9.49

M. Saitoh, H. Nishitoh, M. Fujii, K. Takeda, K. Tobiume et al., Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1, The EMBO Journal, vol.17, issue.9, pp.2596-2606, 1998.
DOI : 10.1093/emboj/17.9.2596

A. Salmeen and D. Barford, Functions and Mechanisms of Redox Regulation of Cysteine-Based Phosphatases, Antioxidants & Redox Signaling, vol.7, issue.5-6, pp.5-6, 2005.
DOI : 10.1089/ars.2005.7.560

I. Sanchez and B. D. Dynlacht, New insights into cyclins, CDKs, and cell cycle control, Seminars in Cell & Developmental Biology, vol.16, issue.3, pp.311-321, 2005.
DOI : 10.1016/j.semcdb.2005.02.007

T. Sandalova, L. Zhong, Y. Lindqvist, A. Holmgren, and G. Schneider, Three-dimensional structure of a mammalian thioredoxin reductase: Implications for mechanism and evolution of a selenocysteine-dependent enzyme, Proceedings of the National Academy of Sciences, vol.332, issue.5482, pp.98-9533, 2001.
DOI : 10.1042/bj3320591

C. Sanmartin-suarez, R. Soto-otero, I. Sanchez-sellero, and E. Mendez-alvarez, Antioxidant properties of dimethyl sulfoxide and its viability as a solvent in the evaluation of neuroprotective antioxidants, Journal of Pharmacological and Toxicological Methods, vol.63, issue.2, pp.209-215, 2011.
DOI : 10.1016/j.vascn.2010.10.004

Y. Sato, H. Sasaki, S. Kondo, I. Fukai, M. Kiriyama et al., Expression of the cdc25B mRNA Correlated with that of N-myc in Neuroblastoma, Japanese Journal of Clinical Oncology, vol.31, issue.9, pp.428-431, 2001.
DOI : 10.1093/jjco/hye093

P. A. Savitsky and T. Finkel, Redox Regulation of Cdc25C, Journal of Biological Chemistry, vol.1176, issue.23, pp.20535-20540, 2002.
DOI : 10.1002/(SICI)1097-4652(199810)177:1<148::AID-JCP16>3.0.CO;2-9

P. T. Schumacker, Reactive oxygen species in cancer cells: Live by the sword, die by the sword, Cancer Cell, vol.10, issue.3, pp.175-176, 2006.
DOI : 10.1016/j.ccr.2006.08.015

J. Seyfried and U. Wullner, Inhibition of Thioredoxin reductase induces apoptosis in neuronal cell lines: Role of glutathione and the MKK4/JNK pathway, Biochemical and Biophysical Research Communications, vol.359, issue.3, pp.759-764, 2007.
DOI : 10.1016/j.bbrc.2007.05.176

L. Shao, M. B. Diccianni, T. Tanaka, R. Gribi, A. L. Yu et al., Thioredoxin expression in primary T-cell acute lymphoblastic leukemia and its therapeutic implication, Cancer Res, pp.61-7333, 2001.

H. D. Soule, J. Vazguez, A. Long, S. Albert, and M. Brennan, A Human Cell Line From a Pleural Effusion Derived From a Breast Carcinoma 2, JNCI: Journal of the National Cancer Institute, vol.51, issue.5, pp.1409-1416, 1973.
DOI : 10.1093/jnci/51.5.1409

J. F. Stevens and C. S. Maier, Acrolein: Sources, metabolism, and biomolecular interactions relevant to human health and disease, Molecular Nutrition & Food Research, vol.110, issue.4, pp.7-25, 2008.
DOI : 10.1289/ehp.02110s4505

A. Szadkowski and C. R. Myers, Acrolein oxidizes the cytosolic and mitochondrial thioredoxins in human endothelial cells, Toxicology, vol.243, issue.1-2, pp.164-176, 2008.
DOI : 10.1016/j.tox.2007.10.004

F. Tas, H. Hansel, A. Belce, S. Ilvan, A. Argon et al., Oxidative Stress in Breast Cancer, Medical Oncology, vol.22, issue.1, pp.11-15, 2005.
DOI : 10.1385/MO:22:1:011

O. Timofeev, O. Cizmecioglu, F. Settele, T. Kempf, and I. Hoffmann, /M Transition, Journal of Biological Chemistry, vol.19, issue.22, pp.16978-16990, 2010.
DOI : 10.1038/sj.emboj.7601136

K. F. Tonissen and G. D. Trapani, Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy, Molecular Nutrition & Food Research, vol.133, issue.235, pp.87-103, 2009.
DOI : 10.1016/S0360-3016(01)01810-7

S. Toyokuni, K. Okamoto, J. Yodoi, and H. Hiai, Persistent oxidative stress in cancer, FEBS Letters, vol.54, issue.1, pp.1-3, 1995.
DOI : 10.1111/j.1432-1033.1991.tb16261.x

D. Trachootham, J. Alexandre, and P. Huang, Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?, Nature Reviews Drug Discovery, vol.104, issue.7, pp.579-591, 2009.
DOI : 10.4161/cbt.7.12.7067

D. Trachootham, W. Lu, M. A. Ogasawara, R. D. Nilsa, and P. Huang, Redox Regulation of Cell Survival, Antioxidants & Redox Signaling, vol.10, issue.8, pp.1343-1374, 2008.
DOI : 10.1089/ars.2007.1957

S. M. Tsao, M. C. Yin, and W. H. Liu, Oxidant Stress and B Vitamins Status in Patients With Non-Small Cell Lung Cancer, Nutrition and Cancer, vol.33, issue.1, pp.8-13, 2007.
DOI : 10.1016/S0955-2863(03)00009-3

S. Ueda, H. Masutani, H. Nakamura, T. Tanaka, M. Ueno et al., Redox Control of Cell Death, Antioxidants & Redox Signaling, vol.4, issue.3, pp.405-414, 2002.
DOI : 10.1089/15230860260196209

M. Ueno, H. Masutani, R. J. Arai, A. Yamauchi, K. Hirota et al., Thioredoxin-dependent Redox Regulation of p53-mediated p21 Activation, Journal of Biological Chemistry, vol.72, issue.50, pp.35809-35815, 1999.
DOI : 10.1002/1097-0142(19920415)69:8<2091::AID-CNCR2820690814>3.0.CO;2-X

S. Urig and K. Becker, On the potential of thioredoxin reductase inhibitors for cancer therapy, Seminars in Cancer Biology, vol.16, issue.6, pp.452-465, 2006.
DOI : 10.1016/j.semcancer.2006.09.004

M. Valko, D. Leibfritz, J. Moncol, M. T. Cronin, M. Mazur et al., Free radicals and antioxidants in normal physiological functions and human disease, The International Journal of Biochemistry & Cell Biology, vol.39, issue.1, pp.44-84, 2007.
DOI : 10.1016/j.biocel.2006.07.001

M. Valko, C. J. Rhodes, J. Moncol, M. Izakovic, and M. Mazur, Free radicals, metals and antioxidants in oxidative stress-induced cancer, Chemico-Biological Interactions, vol.160, issue.1, pp.1-40, 2006.
DOI : 10.1016/j.cbi.2005.12.009

E. A. Veal, A. M. Day, and B. A. Morgan, Hydrogen Peroxide Sensing and Signaling, Molecular Cell, vol.26, issue.1, pp.1-14, 2007.
DOI : 10.1016/j.molcel.2007.03.016

S. Venkataraman, X. Jiang, C. Weydert, Y. Zhang, H. J. Zhang et al., Manganese superoxide dismutase overexpression inhibits the growth of androgen-independent prostate cancer cells, Oncogene, vol.24, issue.1, pp.77-89, 2005.
DOI : 10.1074/jbc.275.18.13175

E. Vergara, A. Casini, F. Sorrentino, O. Zava, E. Cerrada et al., Anticancer Therapeutics That Target Selenoenzymes: Synthesis, Characterization, in??????vitro Cytotoxicity, and Thioredoxin Reductase Inhibition of a Series of Gold(I) Complexes Containing Hydrophilic Phosphine Ligands, ChemMedChem, vol.193, issue.1, pp.96-102, 2010.
DOI : 10.1042/bj3320591

K. Vermeulen, D. R. Van-bockstaele, and Z. N. Berneman, The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer, Cell Proliferation, vol.59, issue.3, pp.131-149, 2003.
DOI : 10.1101/gad.827700

J. F. Viallard, F. Lacombe, F. Belloc, J. L. Pellegrin, and J. Reiffers, M??canismes mol??culaires contr??lant le cycle cellulaire??: aspects fondamentaux et implications en canc??rologie, Cancer/Radioth??rapie, vol.5, issue.2, pp.109-129, 2001.
DOI : 10.1016/S1278-3218(01)00087-7

E. Viry, E. Battaglia, V. Deborde, T. Muller, R. Reau et al., A Sugar-Modified Phosphole Gold Complex with Antiproliferative Properties Acting as a Thioredoxin Reductase Inhibitor in MCF-7 Cells, ChemMedChem, vol.40, issue.11, pp.1667-1670, 2008.
DOI : 10.1002/cmdc.200800210

A. Vogt, K. Tamura, S. Watson, and J. S. Lazo, Antitumor imidazolyl disulfide IV-2 causes irreversible G(2)/M cell cycle arrest without hyperphosphorylation of cyclin-dependent kinase Cdk1, J Pharmacol Exp Ther, vol.294, issue.3, pp.1070-1075, 2000.

G. P. Voulgaridou, I. Anestopoulos, R. Franco, M. I. Panayiotidis, and A. Pappa, DNA damage induced by endogenous aldehydes: Current state of knowledge, Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol.711, issue.1-2, pp.13-27, 2011.
DOI : 10.1016/j.mrfmmm.2011.03.006

D. Wang and S. J. Lippard, Cellular processing of platinum anticancer drugs, Nature Reviews Drug Discovery, vol.11, issue.4, pp.307-320, 2005.
DOI : 10.1016/0006-2952(88)90325-5

L. Wang, Y. Sun, M. Asahi, and K. Otsu, Acrolein, an Environmental Toxin, Induces Cardiomyocyte Apoptosis via Elevated Intracellular Calcium and Free Radicals, Cell Biochemistry and Biophysics, vol.181, issue.1, 2011.
DOI : 10.1016/j.cbi.2009.07.001

Z. Wang, C. G. Trope, V. A. Florenes, Z. Suo, J. M. Nesland et al., Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes, BMC Cancer, vol.5, issue.1, p.233, 2010.
DOI : 10.1038/ncb994

W. H. Watson, J. M. Heilman, L. L. Hughes, and J. C. Spielberger, Thioredoxin reductase-1 knock down does not result in thioredoxin-1 oxidation, Biochemical and Biophysical Research Communications, vol.368, issue.3, pp.832-836, 2008.
DOI : 10.1016/j.bbrc.2008.02.006

S. J. Welsh, W. T. Bellamy, M. M. Briehl, and G. Powis, The redox protein thioredoxin-1, 2002.

C. C. Winterbourn and M. B. Hampton, Thiol chemistry and specificity in redox signaling, Free Radical Biology and Medicine, vol.45, issue.5, pp.549-561, 2008.
DOI : 10.1016/j.freeradbiomed.2008.05.004

A. B. Witte, K. Anestal, E. Jerremalm, H. Ehrsson, and E. S. Arner, Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds, Free Radical Biology and Medicine, vol.39, issue.5, pp.696-703, 2005.
DOI : 10.1016/j.freeradbiomed.2005.04.025

G. T. Wondrak, Redox-Directed Cancer Therapeutics: Molecular Mechanisms and Opportunities, Antioxidants & Redox Signaling, vol.11, issue.12, pp.3013-3069, 2009.
DOI : 10.1089/ars.2009.2541

URL : http://europepmc.org/articles/pmc2824519?pdf=render

H. A. Woo, S. H. Yim, D. H. Shin, D. Kang, D. Y. Yu et al., Inactivation of Peroxiredoxin I by Phosphorylation Allows Localized H2O2 Accumulation for Cell Signaling, Cell, vol.140, issue.4, pp.517-528, 2010.
DOI : 10.1016/j.cell.2010.01.009

C. C. Wu, C. W. Hsieh, P. H. Lai, J. B. Lin, Y. C. Liu et al., Upregulation of endothelial heme oxygenase-1 expression through the activation of the JNK pathway by sublethal concentrations of acrolein, Toxicology and Applied Pharmacology, vol.214, issue.3, pp.244-252, 2006.
DOI : 10.1016/j.taap.2005.12.013

W. Wu, Y. H. Fan, B. L. Kemp, G. Walsh, and L. Mao, Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc, Cancer Res, vol.58, issue.18, pp.4082-4085, 1998.

X. Xing, J. Chen, and M. Chen, Expression of CDC25 Phosphatases in Human Gastric Cancer, Digestive Diseases and Sciences, vol.30, issue.Suppl 3, pp.949-953, 2008.
DOI : 10.3346/jkms.1999.14.5.526

M. Yamada, A. Tomida, H. Yoshikawa, Y. Taketani, and T. Tsuruo, Increased expression of thioredoxin/adult T-cell leukemia-derived factor in cisplatin-resistant human cancer cell lines, Clin Cancer Res, vol.2, issue.2, pp.427-432, 1996.

M. Yamada, A. Tomida, H. Yoshikawa, Y. Taketani, and T. Tsuruo, Overexpression of thioredoxin does not confer resistance to cisplatin in transfected human ovarian and colon cancer cell lines, Cancer Chemotherapy and Pharmacology, vol.40, issue.1, pp.31-37, 1997.
DOI : 10.1007/s002800050621

X. Yang, X. Wu, Y. E. Choi, J. C. Kern, and J. P. Kehrer, Effect of acrolein and glutathione depleting agents on thioredoxin, Toxicology, vol.204, issue.2-3, pp.209-218, 2004.
DOI : 10.1016/j.tox.2004.06.056

A. Yokomizo, M. Ono, H. Nanri, Y. Makino, T. Ohga et al., Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide, Cancer Res, vol.55, pp.4293-4296, 1995.

C. X. Yu, S. Li, and A. R. Whorton, Redox Regulation of PTEN by S-nitrosothiols, Molecular Pharmacology, vol.68, issue.3, pp.847-854, 2005.
DOI : 10.1124/mol.104.010504

L. Yu, U. Kelly, J. N. Ebright, G. Malek, P. Saloupis et al., Oxidative stress-induced expression and modulation of Phosphatase of Regenerating Liver-1 (PRL-1) in mammalian retina, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol.1773, issue.9, pp.1473-1482, 2007.
DOI : 10.1016/j.bbamcr.2007.06.005